Seizures
213
27
32
127
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Published Results
36 trials with published results (17%)
Research Maturity
127 completed trials (60% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
8.0%
17 terminated out of 213 trials
88.2%
+1.7% vs benchmark
22%
47 trials in Phase 3/4
28%
36 of 127 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 127 completed trials
Clinical Trials (213)
PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest
buRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest
Human Cognition During Surgery: Stimulation-based and Cholinergic Modulation
Predisposing Factors for Post-stroke Epilepsy
Electrographic Seizure Management and Neurobehavioral Outcomes in Critically Ill Children
De-identified UNMH EEG Corpus Database Creation With Fully De-identified Clinical Information
Long-Term Follow-Up of a Cohort of Participants Prescribed Epidyolex in France in a Real-life Setting
BHV-7000 Responsive Neurostimulation System (RNS) Study
Study of the Pharmacokinetics, Safety, and Tolerability of ZONISADE in Children 1 Month to 17 Years of Age With Partial-onset Seizures
Investigating Epilepsy: Screening and Evaluation
A Study of the Effectiveness of Risk Minimization Measures Related to Depakine® (Sodium Valproate) in Saudi Arabia
Cholinergic Enhancement of Theta
Glioblastoma Remote Monitoring and Care - Research Protocol
Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy
Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases
Etiology and Treatment of Neonatal Seizure
Pilot Trial of a Clinical Decision-Support App for Managing Emergencies Among Clinicians in a Rural Ugandan Hospital
Short Versus Long-term Levetiracetam in Brain Tumors
Epilepsy Watch After Vascular Events: Frequency, Outcomes, and Risk Markers
Evaluating the Role of Inflammation in Neonatal Epileptogenesis